Turan: The effect of favipiravir versus hydroxychloroquine on clinical and laboratory findings in COVID-19 in healthcare workers

The effect of favipiravir versus hydroxychloroquine on clinical and laboratory findings in COVID-19 in healthcare workers

Turan et al., The Brazilian Journal of Infectious Diseases, doi:10.1016/j.bjid.2022.102328

Turan et al., The effect of favipiravir versus hydroxychloroquine on clinical and laboratory findings in COVID-19 in.., The Brazilian Journal of Infectious Diseases, doi:10.1016/j.bjid.2022.102328

Feb 2022 Source PDF

Twitter
Facebook

All Studies Meta

Retrospective 237 low-risk healthcare workers in Turkey, 123 treated with favipiravir and 114 treated with HCQ, showing lower hospitalization and faster viral clearance with favipiravir, and similar improvement. This study is subject to substantial confounding by time because the patients in each group are from different time periods with an overall period of 10 months including the beginning of the pandemic, resulting in significant differences in variants encountered and SOC. Propensity for hospital admission may also have changed significantly. This study is excluded in meta analysis: substantial confounding by time likely due to separation of groups in different time periods over an extended period of time.

Important missing comments or errors? Let us know.

risk of hospitalization, 79.4% lower, RR 0.21, p = 0.001, treatment 4 of 123 (3.3%), control 18 of 114 (15.8%), NNT 8.0.

recovery time, 11.0% higher, relative time 1.11, p = 0.51, treatment 123, control 114.

time to viral-, 21.6% lower, relative time 0.78, p < 0.001, treatment 123, control 114.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Turan et al., 1 Feb 2022, retrospective, Turkey, peer-reviewed, mean age 33.4, 10 authors, study period 11 March, 2020 - 1 January, 2021, this trial compares with another treatment - results may be better when compared to placebo.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Favipiravir All

Abstract: ARTICLE IN PRESS braz j infect dis. 2022;xxx(xx):102328 The Brazilian Journal of INFECTIOUS DISEASES w w w. e l s e v i e r. c o m / l o c a t e / b j i d Original Article The effect of favipiravir versus hydroxychloroquine on clinical and laboratory ﬁndings in COVID-19 in healthcare Q1 workers X X Q2 b € 1X XDerya XD Bay{rl{ Turan a, D2X X *, D3X XMehtap Menteş bD4X X , D5X XY{ld{ran Ozel D6X X , c _ an cD10X X , D1X XNeşe Ibil du lu aD8X X , D9X XBurcu Aydog € sun Gu € neşdog D12X X , D13X XFu D7X XK{vanç Şerefhanog e e f € neyt Saltu € rk D18X X , D19X XHakan Çelik D20X X D15X XHijran Mammadova Orucova D16X X , D17X XCu d D14X X , € zy{l University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Istanbul Yeni Yu Istanbul, Turkey b € zy{l University Faculty of Medicine, Istanbul, Turkey Department of Occupational Health and Safety, Istanbul Yeni Yu c € zy{l University Faculty of Medicine, Istanbul, Turkey Department of Infection Control Committee, Istanbul Yeni Yu d € zy{l University Faculty of Medicine, Istanbul, Turkey Department of Family Medicine, Istanbul Yeni Yu e € zy{l University Faculty of Medicine, Istanbul, Turkey Department of Chest Diseases, Istanbul Yeni Yu f € zy{l University Faculty of Medicine, Istanbul, Turkey Department of Pharmacology, Istanbul Yeni Yu a A R T I C L E I N F O A B S T R A C T Article history: Objectives: Comparative data on hydroxychloroquine and favipiravir, commonly used Received 4 November 2021 agents in the treatment of Coronavirus Disease-2019 (COVID-19), are still limited. In this Accepted 23 January 2022 study, it was aimed to compare treatment outcomes in healthcare workers with COVID-19 Available online xxx who were prospectively followed by the occupational health and safety unit. Methods: A total of 237 healthcare-workers, diagnosed as mild or moderate COVID-19 Keywords: between March 11, 2020 and January 1, 2021, were given hydroxychloroquine (n = 114) or SARS-CoV-2 favipiravir (n = 123). Clinical and laboratory ﬁndings were evaluated. COVID-19 Results: The mean age of the patients was 33.4§11.5 years. The mean time to negative PCR Hydroxychloroquine was found to be signiﬁcantly shorter in patients receiving favipiravir compared to the Favipiravir hydroxychloroquine group (10.9 vs. 13.9 days; p < 0.001). The rate of hospitalization in the Healthcare workers hydroxychloroquine group was signiﬁcantly higher than favipiravir group (15.8% vs. 3.3%). In terms of side effects; the frequency of diarrhea in patients receiving hydroxychloroquine was signiﬁcantly higher than that in the favipiravir group (31.6% vs. 6.5%; p < 0.001). Conclusions: Favipiravir and hydroxychloroquine were similar in terms of improvement of clinical symptoms of healthcare workers with mild or moderate COVID-19 infection, but favipiravir was signiﬁcantly more effective in reducing viral load and hospitalization rates. Furthermore, favipiravir caused signiﬁcantly less side-effects than hydroxychloroquine. Ó 2022 Published by Elsevier España, S.L.U. on behalf of Sociedade Brasileira de Infectologia. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) € zy{l University Fac* Corresponding author at: Istanbul Yeni Yu Microbiology, Istanbul, Turkey. ulty of Medicine, Department of Infectious Diseases and Clinical E-mail address: deryabturan@gmail.com (D.B...

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit